Swiss Healthtech Stock News

Vontobel Holding (SWX:VONN) closed FY 2025 with second half revenue of CHF 741.7 million and basic EPS of CHF 2.94, while trailing 12 month revenue came in at CHF 1.43 billion with basic EPS of CHF 4.99, setting a clear benchmark for the latest reporting stretch. The company has seen revenue move from CHF 694.3 million and basic EPS of CHF 2.44 in 2024’s second half to CHF 741.7 million and CHF 2.94 respectively in 2025’s second half, with trailing net income of CHF 280.1 million framing a...

Novartis AG ( VTX:NOVN ) will increase its dividend from last year's comparable payment on the 12th of March to $3.70...

Why Vontobel’s latest earnings and dividend matter Vontobel Holding (SWX:VONN) has drawn fresh investor attention after reporting higher full year 2025 net income and earnings per share, together with asset under management growth and an affirmed annual dividend of CHF 3.00 per share. See our latest analysis for Vontobel Holding. The earnings and dividend announcement has coincided with a clear upswing in sentiment, with a 3.83% 1 day share price return and a 16.12% 90 day share price return...

Revenue growth event puts Compagnie Financière Tradition (SWX:CFT) in focus Compagnie Financière Tradition (SWX:CFT) caught investor attention after reporting 2025 consolidated revenue growth of 11.4% at constant exchange rates, with the fourth quarter advancing 11.7% on higher transaction volumes across asset classes and regions. See our latest analysis for Compagnie Financière Tradition. At a share price of CHF289.0, Compagnie Financière Tradition has had a mixed shorter term run, with a 1...

Most readers would already know that Burkhalter Holding's (VTX:BRKN) stock increased by 8.1% over the past three...

It's been a good week for Novartis AG ( VTX:NOVN ) shareholders, because the company has just released its latest...

Barry Callebaut (SWX:BARN) is back in focus after reporting a 22% drop in cocoa division sales volume for the quarter ending November 30, citing weak market demand and a tilt toward higher return cocoa segments. See our latest analysis for Barry Callebaut. The latest cocoa volume setback comes after a period of strong momentum in the share price, with a 12.69% 1 month share price return and an 18.16% 3 month share price return contributing to a 45.54% 1 year total shareholder return, even...

Most readers would already be aware that Swiss Prime Site's (VTX:SPSN) stock increased significantly by 15% over the...

Givaudan SA recently reported its full-year 2025 results, with sales of CHF 7,472 million and net income of CHF 1,071 million, and announced an annual dividend of CHF 72.00 per share payable on March 25, 2026. Despite slightly lower net income and earnings per share than the previous year, the decision to raise the dividend highlights management’s willingness to return more cash to shareholders. We will now examine how Givaudan’s decision to increase its annual dividend despite softer...

As the eurozone economy continues its modest recovery, with improved consumer and business confidence, European markets have shown resilience amidst global trade and geopolitical concerns. In this environment, dividend stocks can offer stability and income potential, making them an attractive option for investors looking to navigate the current market dynamics.

Sensirion Holding AG has launched the SCD53, a highly intrinsically stable CO₂ sensor designed to maintain long-term accuracy without manual recalibration or exposure to outdoor air, while offering integrated humidity, temperature and optional pressure compensation in a compact, easily integrated package. By eliminating reliance on automatic baseline calibration and enhancing robustness against dust, vibrations and mechanical stress, the SCD53 directly targets challenging applications such...

As the European markets navigate a landscape marked by earnings optimism amidst trade and geopolitical concerns, the pan-European STOXX Europe 600 Index has shown resilience with modest gains. Against this backdrop, identifying stocks that are trading below their estimated worth can offer potential opportunities for investors seeking value in an environment where confidence is strengthening and economic recovery continues at a steady pace.

Galderma recently announced that the U.S. FDA has accepted its resubmitted Biologics License Application for RelabotulinumtoxinA, a neuromodulator for treating moderate-to-severe frown lines and crow’s feet in adults, following manufacturing process adjustments and backed by large phase III trial data. This milestone builds on Relfydess’s approvals in more than 20 markets and highlights Galderma’s efforts to broaden its injectable aesthetics franchise worldwide. We’ll now examine how the...

Idorsia has recently announced an exclusive license and supply agreement with EMS S.A. to register and commercialize its insomnia medicine QUVIVIQ (daridorexant) across Latin America, while also presenting long-term data on lucerastat suggesting disease-modifying potential in Fabry disease at the WORLDSymposium. Together, these developments highlight Idorsia’s push to expand QUVIVIQ into new geographies and progress lucerastat toward a defined regulatory path in a rare disease setting. We’ll...

In January 2026, BlackRock and Partners Group launched a first-of-its-kind multi-alternatives separately managed account on the Morgan Stanley wealth platform, giving advisors streamlined access to diversified private equity, private credit, and real assets through three outcome-aligned strategies. This structure is designed to remove common barriers to private market access by consolidating seven evergreen private market funds into a single, operationally simple solution for financial...

Cosmo Pharmaceuticals N.V. recently completed a private placement of 937,086 treasury shares, equivalent to about 5.3% of its outstanding shares, with Capital Group’s SMALLCAP World Fund, using only existing treasury stock and therefore avoiding dilution for current shareholders. The deal brings a globally recognized institutional investor into Cosmo’s shareholder base while providing additional financial flexibility to support its MedTech AI, dermatology, gastroenterology, and CDMO...

ams-OSRAM’s ongoing turnaround has involved restructuring and moving away from low-margin LED activities toward automotive and industrial optical semiconductor applications, with management stressing operational improvements and debt reduction as priorities. An interesting angle is how investors and analysts are closely watching AI-driven demand for optical sensors as a potential earnings catalyst, while still highlighting considerable execution and leverage risks. Next, we’ll examine how...

As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...

BD and Ypsomed Holding (SWX:YPSN) are expanding their collaboration around a new 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe, tailored for Ypsomed’s YpsoMate 5.5 large volume autoinjector platform. See our latest analysis for Ypsomed Holding. Despite the expanded BD partnership around large volume injectors, Ypsomed Holding’s 1 day share price return of 0.16% comes after a softer patch, with a 30 day share price return of 6.71% and a 1 year total shareholder return of 12.36%. This...

Adecco Group’s LHH brand recently launched a global HR and talent consulting business, aiming to expand its higher-value advisory and support offerings. This move signals a push toward more consultative, margin-rich services that could reshape how Adecco balances traditional staffing with broader workforce solutions. Next, we’ll examine how this LHH consulting launch influences Adecco’s investment narrative, particularly its push into higher-margin HR services. Trump's oil boom is here -...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Mitsubishi Electric Corporation and Landis+Gyr Group (SWX:LAND) have signed a Memorandum of Understanding to work together on grid edge intelligence and energy transition solutions, initially targeting North American utilities. See our latest analysis for Landis+Gyr Group. The Mitsubishi Electric agreement lands after a recent Q3 sales or trading statement call and comes as the share price sits at CHF54.3, with a 7 day share price return of 6.68% but a 1 year total shareholder return of 8.23%...

In January 2026, BELIMO Holding AG reported its 2025 results, revealing accelerated sales growth of 23.3% in local currencies and CHF 1,121 million in sales. This sharp step-up in growth relative to the prior year highlights how BELIMO’s offering is gaining traction across its key end markets. We’ll now examine how this acceleration in sales growth shapes BELIMO’s investment narrative and what it could mean for investors. The end of cancer? These 29 emerging AI stocks are developing tech...

Shareholders of ABB Ltd ( VTX:ABBN ) will be pleased this week, given that the stock price is up 10% to CHF66.66...